Acute and Repeated Toxicological Study of Anti-Inflammatory Herbal Formula, Yeosinsan, in Rats

Abstract

Yeosinsan, an herbal formula composed of roots of Paeonia lactiflora and tubers of Cyperus rotundus, was reported as a possible anti-inflammatory and pro-fertility drug. However, the safety of Yeosinsan has not yet been previously investigated. The possible acute and chronic oral toxicity of Yeosinsan was estimated using female and male Sprague Dawley rats. During the administration period, rats were monitored for mortality, body weight changes, food intake, clinical signs, and gross findings. Hematological analysis, serum biochemistry analysis, urinalysis, organ weight measurement, and histopathological examination were also conducted after sacrifice. Acute and chronic oral administration of Yeosinsan did not result in any signs of toxicity in the animals during the observation period. However, in the histopathological examination, several significant changes were observed in the stomach and spleen. In the high-dose group, extramedullary hematopoiesis and increased pigmentation in the spleen and squamous cell hyperplasia in the forestomach were observed. In conclusion, the no observed adverse effect level (NOAEL) of the test material, Yeosinsan, was estimated at 1000 mg∙kg⁻¹∙d⁻¹ for both male and female rats. Therefore, our data suggest that Yeosinsan might be safe to use for treating female infertility.

1. Introduction

Although the development of assisted reproduction technologies in recent decades has improved the outcomes of infertility treatment, a poor ovarian response and repetitive implantation failure are still major issues in female infertility [1,2]. Because there are very limited options for improving ovarian function and endometrial receptivity [3], many researchers have struggled to find novel therapeutic agents. Traditional medicines have been used for treating female infertility in many countries such as Korea, Japan, and China [4]. The effects of traditional herbal formulas, such as BaelanChagsangBang, Zhuyun recipe, Erbuzhuyu decoction, Dingkun Pill, and Wenshen Yangxue decoction, were previously studied [5,6,7,8,9]. Several studies have focused on ovarian dysfunction and defective endometrial receptivity as the molecular mechanism of these herbal remedies [10,11].

Paeonia lactiflora Pall. (Paeoniae Radix) and its major ingredient, paeoniflorin, have anti-inflammatory effects on several diseases, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and asthma [12,13]. Cyperus rotundus L. (Cyperi Rhizoma) is also used for anti-oxidative and anti-inflammatory purposes [14,15]. In our previous study, the roots of P. lactiflora and the tubers of C. rotundus were able to treat female infertility by enhancing endometrial receptivity [16,17]. The possible effect of P. lactiflora on ovarian function was also reported in clinical studies on patients with polycystic ovarian disease [18,19,20]. In addition, Yeosinsan, an herbal formula composed of these two herbal medicines, was traditionally used for inflammation-related uterine bleeding and reported as a possible drug for improving female fertility that activates ovarian function and endometrial receptivity [21]. However, in the case of safety experiments, there are no reports on good laboratory practice (GLP)-level safety experiments of these herbal formulas, including BaelanChagsangBang, Zhuyun recipe, Erbuzhuyu decoction, Dingkun Pill, and Wenshen Yangxue decoction. In addition, very limited previous reports were found on the safety of these herbal medicines, including P. lactiflora and C. rotundus, or Yeosinsan [14,22].

Thus, in this study, we evaluated the possible acute and chronic oral toxicity of Yeosinsan using a GLP rat model according to standard toxicology protocols. The safety data for Yeosinsan might play a crucial role in the approval of an investigational new drug application and in the protection of human subjects in clinical trials.

2. Materials and Methods

2.1. Preparation of Yeosinsan Extract

The extract of the herbal formula, Yeosinsan, was supplied by Cho-A Pharmaceutical Co. (Seoul, Korea). The Yeosinsan extract was prepared at a GMP-level facility at Cho-A Pharmaceutical Co., according to our previous protocol [21], and stored at the company under the codename CHOA_PLCR. Briefly, 4 kg of the two mixed herbal medicines (P. lactiflora and roasted C. rotundus with aqueous alcohol) was boiled in distilled water. The hGMP-level product of herbs according to the Ministry of Food and Drug Safety (MFDS) guideline was purchased from Green Myungpum Pharm (Namyangju, Korea), collected at Gyeongbuk province, Korea in 2019. The voucher specimens were deposited in the herbarium of Cho-A Pharmaceutical Co. The extract was concentrated and converted to a powder via a spray-drying process. The weight of the final extracted powder was 392 g (yield = 9.8%). After the powder was dissolved in distilled water, it was filtered and stored until use.

2.2. Animals

The preclinical safety experiment was conducted by the Korea Institute of Toxicology (KIT, Daejeon, Korea), according to the guideline for the Care and Use of Laboratory Animal and the good laboratory practice (GLP) guideline (2019) of the MFDS, Government of Korea. All experimental designs were approved by the Institutional Animal Care and Use Committee (KIT experiment protocol number G217055 and G218038). KIT was approved by the Association for Assessment and Accreditation of Laboratory Animal Care International in 1998. Healthy animals were used for this test, and inspection reports provided by the animal suppliers were maintained as basic data. The animals selected in this study did not show clinical symptoms such as illness or injury and presented appropriate body weights. Sprague Dawley (SD) rats with a body weight of 189.2 to 216.3 g for males and 140.0 to 170.4 g for females were supplied by Orient Bio (Sungnam, Korea). Based on the most recent body weight, the Pristima System (Xybion Co., Lawrenceville, NJ) was used to randomly assign the rats to control and administration groups. The environment was automatically controlled according to standard working conditions (temperature: 23 ± 3 °C, relative humidity: 30–70%, 12-h light/12-h dark cycle, illumination: 150–300 lux, ventilation: 10–20 times per hour). The temperature and relative humidity were automatically monitored and recorded. At the end of experiments, animals were fasted for 12 h and euthanized with an inhalation of isoflurane (JSK, Goyang, Korea).

2.3. Acute Oral Toxicity

To investigate the acute oral toxicity of Yeosinsan in rats, this test was conducted using a single oral dose of 0, 500, 1000, or 2000 mg/kg in each of the five male and female groups. The experimental animals were monitored for mortality, body weight changes, food intake, clinical signs, and gross findings during the administration period. Yeosinsan extract was administered once, and the observation period was 15 days after administration.

2.4. Chronic Toxicity Test

Yeosinsan was administered to male and female SD rats at oral doses of 0, 500, 1000, and 2000 mg∙kg⁻¹∙d⁻¹. The experimental animals were monitored for mortality, body weight changes, food intake, clinical signs, and gross findings during the administration period. Organ weight, histopathological, hematological, and biochemical analyses were also conducted after sacrifice. Yeosinsan extract was administered once a day during every observation day. The observation period was 92 days for males and 93 days for females.

2.5. Hematology and Serum Biochemical Analysis

For hematological analysis, total leukocyte count (WBC), mean corpuscular hemoglobin (MCH), total red blood cell count (RBC), mean corpuscular hemoglobin concentration (MCHC), hemoglobin (HGB), platelet count (PLT), hematocrit (HCT), reticulocyte count, mean corpuscular volume (MCV), and WBC differential counts were measured using an ADVIA 2120i hematology analyzer (Siemens, Munich, Germany). Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using an ACL Elite Pro Coagulation Analyzer (Instrumentation Laboratory, Bedford, MA). About 1.5 mL of blood was collected from each animal. About 0.5 mL of blood was collected in a blood collection tube containing an anticoagulant (EDTA-2K) for hematological analysis. About 1.0 mL of blood was collected in a blood collection tube containing 3.2% sodium citrate. The plasma was separated by centrifugation (approximately 3000 rpm for 10 min at room temperature), and a blood clotting time test was conducted.

For serum biochemical analysis, glucose (GLU), alanine aminotransferase (ALT), blood urea nitrogen (BUN), total bilirubin (TBIL), creatinine (CREA), alkaline phosphatase (ALP), total protein (TP), gamma-glutamyl transpeptidase (GGT), albumin (ALB), creatine phosphokinase (CK), the albumin/globulin ratio (A/G), calcium (Ca), total cholesterol (TCHO), inorganic phosphorus (IP), triglyceride (TG), sodium (Na), phospholipid (PL), potassium (K), aspartate aminotransferase (AST), and chloride (Cl) were measured using a TBA120FR chemistry analyzer (Toshiba Co., Tokyo, Japan). Before blood collection, all animals were fasted for more than 16 h. About 1.5 mL of blood was collected in a tube without anticoagulants. After incubation at room temperature for at least 90 min, the serum was separated by centrifugation (approximately 3000 rpm for 10 min at room temperature).

2.6. Urinalysis

For urinalysis, urine volume (VOL) was measured by reading the scales on the urine collection tube. Clarity (CLA) was examined visually. After visual examination, the data were input into Cobas U411. Glucose (GLU), color (COL), erythrocyte (ERY), pH, ketone (KETu), specific gravity (SG), leukocytes (LEU), bilirubin (BILu), protein (PRO), urobilinogen (UBG), and nitrite (NIT) were measured using a Cobas U411 urine analyzer (Roche, Germany) and Combur 10 TM urine sticks (Roche, Germany). Urine potassium (UK), chloride (UCl), and sodium (UNa) were measured using a TBA 120FR automated chemistry analyzer (Toshiba, Japan). Urine was collected from all animals for about 16 h within the week before necropsy.

2.7. Necropsy and Histopathology

After the test period, all remaining animals were euthanized using CO₂ inhalation. A full detailed gross necropsy was conducted for each dose group. The weights of the following organs were measured for all animals: brain, kidneys, pituitary gland, adrenal glands, liver, testes, spleen, epididymis, heart, lung, thymus, thyroids (with parathyroids), salivary glands (submandibular and sublingual), uterus (with cervix), seminal vesicles (with coagulation gland), ovaries, and prostate. Reference samples were saved for all animals and visible abnormalities in the control group and highest dose group, and histopathological examination was conducted after hematoxylin and eosin staining. Reference samples were also saved for the 500 and 1000 mg∙kg⁻¹∙d⁻¹ dose groups for the stomach and spleen, where changes due to the test substance were observed, and histopathological examination was conducted.

2.8. Statistical Analysis

The data collected during the test period are presented as the inter-group mean and standard deviation. The data were statistically analyzed using the Pristima System (Xybion Co., Lawrenceville, NJ, USA). The inter-group comparison of the control and administration groups was conducted using a multiple comparison analysis. The parameters tested included body weight, body weight gain, food consumption, hematology, coagulation, clinical chemistry, urinalysis, and organ weight. The data were tested for equal variances using Bartlett’s test, the equally distributed data were tested using one-way analysis of variance, and the differences between groups were analyzed using Dunnett’s test. The least significant difference (LSD) was set as P < 0.05 in all statistical analyses.

3. Results

3.1. Acute Oral Toxicity

The acute oral administration of Yeosinsan extract (single oral dose of 500, 1000, and 2000 mg/kg) did not result in any signs of toxicity in the animals during the 15 days of the observation period (

Table 1. Summary of clinical signs of acute oral toxicity.

Dosage Group (mg/kg)			0	500	1000	2000
Male	No abnormalities detected	Number of animals examined	5	5	5	5
		Number of animals not affected	5	5	5	5
		Mean number of animal days with no clinical sign	15	15	15	15
Female	No abnormalities detected	Number of animals examined	5	5	5	5
		Number of animals not affected	5	5	5	5
		Mean number of animal days with no clinical sign	15	15	15	15

). Regarding body weight, no weight changes associated with the test substance were observed in any dose group (Figure 1). In the microscopic observations, no changes associated with the test substance were observed in any dose group (Table S1). Regarding mortality, no dead animals were observed during the test period (Table S2).

3.2. Chronic oral Toxicity

3.2.1. Clinical Signs and Mortality

The chronic oral administration of Yeosinsan extract did not result in any signs of toxicity in the animals during the observation period (92 days for males and 93 days for females). In the male control group, in one subject (animal no. 1), loss of fur and scabbing were observed from day 28 to day 36 after administration. In the female 500 mg∙kg⁻¹∙d⁻¹ dose group, in two subjects (animal no. 51 and 53), loss of fur was observed from 61 days (posterior cranium) and 71 days (right upper forelimb) to 93 days after administration. In the female 2000 mg∙kg⁻¹∙d⁻¹ dose group, in two subjects (animal no. 79 and 80), loss of fur was observed from 71 days (animal no. 79, right neck) and 82 days (animal no. 80, left lumbar region) to 93 days after administration. These symptoms were considered to be the result of repeated physical stimulation during the animal handling process for oral administration (

Table 2. Summary of clinical signs of chronic oral toxicity.

Dosage Group (mg∙kg−1∙d−1)			0	500	1000	2000
Male		Number of animals examined	10	10	10	10
	No abnormalities detected	Number of animals not affected	10	10	10	10
		Mean number of animal days with no clinical sign	91.10	92.00	92.00	92.00
	Fur, hair, coat	Number of animals examined	10	10	10	10
	Loss of fur, posterior neck, slight	Number of animals affected	1	0	0	0
		Mean number of animal days with clinical sign	9.00	0.00	0.00	0.00
	Skin	Number of animals examined	10	10	10	10
	Scab, posterior neck, slight	Number of animals affected	1	0	0	0
		Mean number of animal days with clinical sign	9.00	0.00	0.00	0.00
Female		Number of animals examined	10	10	10	10
	No abnormalities detected	Number of animals not affected	10	10	10	10
		Mean number of animal days with no clinical sign	93.00	86.40	93.00	89.50
	Fur, hair, coat	Number of animals examined	10	10	10	10
	Loss of fur, left lumbar region, slight	Number of animals affected	0	0	0	1
		Mean number of animal days with clinical sign	0.00	0.00	0.00	12.00
		Number of animals examined	10	10	10	10
	Loss of fur, posterior cranium, slight	Number of animals affected	0	2	0	0
		Mean number of animal days with clinical sign	0.00	33.00	0.00	0.00
		Number of animals examined	10	10	10	10
	Loss of fur, right neck, slight	Number of animals affected	0	0	0	1
		Mean number of animal days with clinical sign	0.00	0.00	0.00	23.00
		Number of animals examined	10	10	10	10
	Loss of fur, right upper forelimb, slight	Number of animals affected	0	2	0	0
		Mean number of animal days with clinical sign	0.00	23.00	0.00	0.00

).

Regarding mortality, no dead animals were observed during the test period (Table S3).

3.2.2. Body Weight and Feed Intake

Regarding body weight, in the female 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), weight loss was observed, which was statistically significant compared to that in the control group (G1), at 8 days and 36 days after administration (Figure 2). Regarding food consumption, in the female 1000 mg∙kg⁻¹∙d⁻¹ dose group (G3), there was a decrease in food consumption, which was statistically significant compared to that in the control group (G1), at 78 days after administration. In the female 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), there was a decrease in food consumption, which was statistically significant compared to that in the control group (G1), at 8 days after administration (Figure 3).

3.2.3. Organ Weight

Regarding the absolute organ weight, in the male 2000 mg∙kg⁻¹∙d⁻¹ dose group, the absolute and relative weight gain of the kidneys (1.18 and 1.13 times, respectively) and the relative weight loss of the epididymis (0.87 times) were statistically significant. In the female dose groups at or over 1000 mg∙kg⁻¹∙d⁻¹, relative weight gain was observed in the spleen (maximum 1.22 times). These changes were considered to be unrelated to the test substance because either histological changes were not observed or the changes were caused by specific objects (

Table 3. Effects of chronic oral administration of Yeosinsan extract on absolute organ weights.

Dosage Group (mg∙kg−1∙d−1)		0	500	1000	2000
Male	TBW (g)	546.1 ± 79.76	543.6 ± 42.11	551.0 ± 49.88	565.0 ± 42.30
	(ADRG) Adrenal glands (g)	0.062 ± 0.0096	0.063 ± 0.0072	0.065 ± 0.0110	0.064 ± 0.0042
	(BRA) Brain (g)	2.163 ± 0.1352	2.214 ± 0.0803	2.174 ± 0.0824	2.214 ± 0.0878
	(HT) Heart (g)	1.706 ± 0.2359	1.584 ± 0.1162	1.641 ± 0.1242	1.679 ± 0.1135
	(KID) Kidneys (g)	3.625 ± 0.3945	3.958 ± 0.3891	4.065 ± 0.4607	4.280 ± 0.4100 **
	(LIV) Liver (g)	15.464 ± 3.4509	15.848 ± 2.1123	15.676 ± 2.0249	16.580 ± 1.3323
	(PITG) Pituitary glands (g)	0.014 ± 0.0033	0.015 ± 0.0025	0.013 ± 0.0016	0.013 ± 0.0015
	(SPL) Spleen (g)	0.925 ± 0.2494	0.903 ± 0.1138	0.916 ± 0.0730	1.068 ± 0.2334
	(TES) Testes (g)	3.517 ± 0.3382	3.515 ± 0.3207	3.516 ± 0.2252	3.319 ± 0.7046
	(THY) Thymus (g)	0.478 ± 0.1020	0.446 ± 0.1158	0.449 ± 0.0757	0.463 ± 0.1338
	(SALG) Salivary glands (g)	0.754 ± 0.1519	0.714 ± 0.0505	0.765 ± 0.0780	0.783 ± 0.0553
	(EPI) Epididymis (g)	1.603 ± 0.1721	1.610 ± 0.1146	1.520 ± 0.0698	1.453 ± 0.2286
	(LUN) Lung (g)	1.721 ± 0.1855	1.772 ± 0.1125	1.714 ± 0.0862	1.836 ± 0.0848
	(THPA) Thyroid and parathyroid glands (g)	0.024 ± 0.0058	0.028 ± 0.0069	0.023 ± 0.0028	0.025 ± 0.0043
	(SVCG) Seminal vesicles with coagulating gland	1.983 ± 0.4411	1.877 ± 0.4002	1.805 ± 0.2810	1.702 ± 0.3097
	(PROS) Prostate (g)	0.606 ± 0.1249	0.613 ± 0.1515	0.581 ± 0.1695	0.621 ± 0.1494
Female	TBW (g)	309.4 ± 26.33	300.5 ± 20.04	292.2 ± 19.22	290.4 ± 29.27
	(ADRG) Adrenal glands (g)	0.081 ± 0.0062	0.082 ± 0.0129	0.078 ± 0.0084	0.077 ± 0.0154
	(BRA) Brain (g)	1.997 ± 0.0653	2.019 ± 0.0769	1.987 ± 0.0634	1.969 ± 0.0583
	(HT) Heart (g)	1.046 ± 0.0966	1.054 ± 0.0735	0.974 ± 0.0904	0.964 ± 0.0835
	(KID) Kidneys (g)	2.321 ± 0.2309	2.303 ± 0.1974	2.246 ± 0.1541	2.297 ± 0.2777
	(LIV) Liver (g)	8.729 ± 1.1196	8.443 ± 0.7715	8.377 ± 0.4921	8.611 ± 0.9457
	(OVA) Ovaries (g)	0.098 ± 0.0249	0.095 ± 0.0156	0.084 ± 0.0139	0.093 ± 0.0197
	(PITG) Pituitary glands (g)	0.021 ± 0.0043	0.018 ± 0.0032	0.019 ± 0.0036	0.020 ± 0.0041
	(SPL) Spleen (g)	0.574 ± 0.0379	0.611 ± 0.1084	0.657 ± 0.0855	0.661 ± 0.1035
	(THY) Thymus (g)	0.343 ± 0.0581	0.329 ± 0.0683	0.331 ± 0.0479	0.344 ± 0.0899
	(SALG) Salivary glands (g)	0.466 ± 0.0690	0.458 ± 0.0476	0.449 ± 0.0369	0.471 ± 0.0413
	(LUN) Lung (g)	1.347 ± 0.1355	1.346 ± 0.0768	1.329 ± 0.0896	1.344 ± 0.1263
	(THPA) Thyroid and parathyroid glands (g)	0.019 ± 0.0039	0.020 ± 0.0037	0.019 ± 0.0025	0.019 ± 0.0036
	(UTEC) Uterus/cervix	0.725 ± 0.1570	0.903 ± 0.4507	0.741 ± 0.3030	0.741 ± 0.3344

Data are expressed as the mean ± SD, n = 10 animals per group. ** p < 0.01 according to Dunnett’s LSD test.

, Table S4).

3.2.4. Hematological Test

In the hematological examination, in the female 500 mg∙kg⁻¹∙d⁻¹ and all groups at or over 1000 mg∙kg⁻¹∙d⁻¹ (G3, G4), a decrease (minimum 0.90 times) in RBC and an increase (maximum 1.49 times and 1.58 times, respectively) in the absolute and relative reticulocyte count (RETA and RET%) were observed. In the 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), an increase (maximum 1.07 times) in MCV and MCH was observed (

Table 4. Effects of chronic oral administration of Yeosinsan extract on hematology.

Dosage Group (mg∙kg−1∙d−1)		0	500	1000	2000
Male	RBC (×106/μL)	9.06 ± 0.626	8.70 ± 0.371	8.40 ± 0.337 **	8.21 ± 0.347 **
	HGB (g/dL)	15.6 ± 0.54	15.3 ± 0.37	15.1 ± 0.53	15.2 ± 0.41
	HCT (%)	50.8 ± 1.96	49.7 ± 1.23	48.9 ± 2.14	49.2 ± 1.61
	MCV (fL)	56.2 ± 2.71	57.2 ± 2.2	58.3 ± 1.78	60.0 ± 2.14 **
	MCH (pg)	17.4 ± 1.06	17.7 ± 0.8	17.9 ± 0.55	18.6 ± 0.65 **
	MCHC (g/dL)	30.8 ± 0.68	30.9 ± 0.56	30.8 ± 0.5	30.9 ± 0.47
	RET% (%)	2.03 ± 0.453	2.25 ± 0.412	2.76 ± 0.366 **	3.21 ± 0.352 **
	RETA (×109/μL)	181.9 ± 30.02	194.1 ± 28.71	231.5 ± 27.26 **	263.5 ± 27.76 **
	PLT (×105/μL)	884.8 ± 241.68	996.4 ± 95.96	1036.3 ± 148.98	989.3 ± 219.31
	NEU% (%)	14.9 ± 5.49	16.5 ± 5.01	14.7 ± 4.78	16.1 ± 5.57
	LYM% (%)	79.7 ± 5.7	78.2 ± 5.45	80.5 ± 4.35	78.6 ± 6.26
	EOS% (%)	1.2 ± 0.49	1.3 ± 0.22	1.1 ± 0.28	1 ± 0.37
	MON (%)	2.7 ± 0.76	2.4 ± 0.77	2.4 ± 0.95	2.5 ± 0.85
	BAS% (%)	0.4 ± 0.09	0.4 ± 0.11	0.4 ± 0.13	0.5 ± 0.15
	LUC% (%)	1.1 ± 0.6	1.3 ± 0.65	1 ± 0.4	1.3 ± 0.67
	WBC (×103/μL)	11.95 ± 2.923	10.76 ± 2.25	9.23 ± 1.877	10.35 ± 2.063
	NEUA (×103/μL)	1.76 ± 0.75	1.79 ± 0.695	1.32 ± 0.372	1.68 ± 0.801
	LYMA (×103/μL)	9.55 ± 2.582	8.39 ± 1.67	7.47 ± 1.768	8.11 ± 1.524
	MONA (×103/μL)	0.32 ± 0.107	0.26 ± 0.119	0.22 ± 0.085	0.26 ± 0.135
	EOSA (×103/μL)	0.14 ± 0.054	0.14 ± 0.047	0.1 ± 0.036	0.1 ± 0.04
	BASA (×103/μL)	0.05 ± 0.012	0.05 ± 0.016	0.04 ± 0.016	0.05 ± 0.016
	LUCA (×103/μL)	0.14 ± 0.089	0.15 ± 0.111	0.09 ± 0.043	0.14 ± 0.104
Female	RBC (×106/μL)	8.23 ± 0.355	7.91 ± 0.236 *	7.91 ± 0.285 *	7.44 ± 0.277 **
	HGB (g/dL)	15.5 ± 0.56	15.2 ± 0.61	15.1 ± 0.70	14.8 ± 0.39
	HCT (%)	49.2 ± 1.61	47.5 ± 1.68	47.9 ± 2.43	46.2 ± 1.07 **
	MCV (fL)	59.8 ± 1.38	60.0 ± 1.04	60.5 ± 1.75	62.1 ± 0.96 **
	MCH (pg)	18.9 ± 0.36	19.2 ± 0.46	19.0 ± 0.57	19.9 ± 0.33 **
	MCHC (g/dL)	31.5 ± 0.46	31.9 ± 0.67	31.5 ± 0.42	32.1 ± 0.32 *
	RET% (%)	2.10 ± 0.367	2.73 ± 0.296 **	3.27 ± 0.375 **	2.98 ± 0.486 **
	RETA (×109/μL)	173.3 ± 30.99	216.1 ± 23.02 **	258.9 ± 34.10 **	220.9 ± 33.50 **
	PLT (×105/μL)	996.1 ± 96.69	1052.1 ± 105.30	1074.4 ± 78.18	1087.1 ± 137.76
	NEU% (%)	11.4 ± 5.63	12.8 ± 2.93	12.7 ± 5.93	12.3 ± 4.25
	LYM% (%)	83.4 ± 5.78	81.1 ± 4.41	82.1 ± 6.21	82.8 ± 4.90
	EOS% (%)	1.3 ± 0.39	1.4 ± 0.55	1.1 ± 0.26	1.1 ± 0.52
	MON (%)	2.4 ± 0.88	2.9 ± 1.32	2.3 ± 0.57	2.1 ± 0.60
	BAS% (%)	0.4 ± 0.15	0.5 ± 0.16	0.6 ± 0.21	0.5 ± 0.32
	LUC% (%)	1.1 ± 0.41	1.4 ± 0.59	1.2 ± 0.24	1.3 ± 0.53
	WBC (×103/μL)	7.82 ± 2.014	7.85 ± 1.463	6.4 ± 0.911	8.26 ± 2.354
	NEUA (×103/μL)	0.88 ± 0.478	1.01 ± 0.295	0.79 ± 0.331	0.98 ± 0.358
	LYMA (×103/μL)	6.54 ± 1.910	6.35 ± 1.176	5.28 ± 0.998	6.88 ± 2.152
	MONA (×103/μL)	0.19 ± 0.068	0.23 ± 0.118	0.15 ± 0.035	0.17 ± 0.074
	EOSA (×103/μL)	0.10 ± 0.029	0.12 ± 0.063	0.07 ± 0.019	0.09 ± 0.053
	BASA (×103/μL)	0.03 ± 0.010	0.04 ± 0.013	0.04 ± 0.017	0.04 ± 0.017
	LUCA (×103/μL)	0.09 ± 0.042	0.11 ± 0.055	0.07 ± 0.017	0.1 ± 0.043

Data are expressed as the mean ± SD, n = 10 animals per group. * p < 0.05, ** p < 0.01 according to Dunnett’s LSD test.

). In the 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), an increase (maximum 1.20 times) in PT was observed. These changes were considered to have no toxicological significance because either the values were within the physiologically normal range or associated findings were not observed in the histopathological examination. The other statistically significant changes observed were not associated with the test substance because of a lack of dose correlation, a slight difference from the control group (G1), or values within the physiologically normal range (

Table 5. Effects of chronic oral administration of Yeosinsan extract on coagulation.

Dosage Group (mg∙kg−1∙d−1)		0	500	1000	2000
Male	PT (sec)	15.7 ± 1.36	17.1 ± 2.58	16.6 ± 1.85	18.8 ± 2.06 **
	APTT (sec)	17.2 ± 1.10	17.5 ± 1.10	17.5 ± 0.91	17.2 ± 0.95
Female	PT (sec)	13.8 ± 0.65	14.1 ± 0.58	14.2 ± 0.81	14.8 ± 0.64 *
	APTT (sec)	14.7 ± 1.15	15.4 ± 1.35	15.6 ± 1.02	15.6 ± 0.79

Data are expressed as the mean ± SD, n = 10 animals per group. * P < 0.05, ** P < 0.01 according to Dunnett’s LSD test.

).

3.2.5. Serum Biochemistry

In the serum biochemistry examination, in the female dose groups at or over 1000 mg∙kg⁻¹∙d⁻¹, an increase (maximum 1.46 times) in TBIL was observed. In the female dose groups at or over 1000 mg∙kg⁻¹∙d⁻¹, an increase (maximum 1.46 times) in TBIL was observed. The other statistically significant changes observed were not associated with the test substance because of no dose correlation or a slight difference from the control group (G1) or physiologically normal range (

Table 6. Summary of clinical chemistry of chronic oral toxicity.

Dosage Group (mg∙kg−1∙d−1)		0	500	1000	2000
Male	GUN (mg/dL)	125.9 ± 36.61	116.0 ± 27.93	111.0 ± 17.16	108.3 ± 13.00
	BUN (mg/dL)	16.0 ± 1.56	15.8 ± 2.62	15.1 ± 1.59	16.9 ± 1.56
	CREA (mg/dL)	0.48 ± 0.043	0.47 ± 0.032	0.46 ± 0.020	0.47 ± 0.044
	TP (g/dL)	6.65 ± 0.297	6.55 ± 0.195	6.53 ± 0.339	6.52 ± 0.120
	ALB (g/dL)	4.22 ± 0.144	4.21 ± 0.101	4.22 ± 0.140	4.23 ± 0.091
	A/G (ratio)	1.74 ± 0.102	1.80 ± 0.098	1.83 ± 0.105	1.86 ± 0.103
	AST (IU/L)	126.1 ± 30.47	109.5 ± 15.01	106.0 ± 19.54	107.2 ± 16.12
	ALT (IU/L)	35.0 ± 9.63	29.4 ± 5.17	28.6 ± 4.56	30.8 ± 5.60
	TBIL (mg/dL)	0.126 ± 0.0392	0.113 ± 0.0251	0.140 ± 0.0193	0.142 ± 0.0147
	GGT (IU/L)	1.15 ± 1.246	0.43 ± 0.250	0.34 ± 0.118	0.31 ± 0.181
	ALP (IU/L)	268.3 ± 57.76	298.8 ± 69.89	258.3 ± 57.83	293.5 ± 68.38
	TCHO (mg/dL)	65.7 ± 20.54	57.6 ± 21.09	56.1 ± 17.60	49.0 ± 9.33
	TG (mg/dL)	41.7 ± 21.23	27.4 ± 14.37	34.2 ± 15.89	24.8 ± 12.73
	Ca (mg/dL)	10.90 ± 0.351	10.78 ± 0.354	10.77 ± 0.418	10.95 ± 0.236
	IP (mg/dL)	8.97 ± 0.823	9.41 ± 1.096	9.83 ± 0.854	10.04 ± 0.556 *
	K (mmol/L)	7.24 ± 1.561	8.17 ± 1.279	9.19 ± 0.731 **	9.16 ± 0.819 **
	CK (IU/L)	636.7 ± 205.21	594.3 ± 132.46	580.4 ± 224.39	557.6 ± 204.43
	PL (mg/dL)	100.0 ± 18.74	89.8 ± 24.06	90.0 ± 18.80	83.0 ± 11.18
	Na (mmol/L)	142.6 ± 1.71	142.4 ± 0.97	142.8 ± 0.63	143.8 ± 0.63
	Cl (mmol/L)	98.7 ± 1.70	99.1 ± 1.66	99.6 ± 1.35	99.8 ± 1.23
Female	GUN (mg/dL)	124.3 ± 28.13	122.5 ± 36.14	120.2 ± 17.63	123.1 ± 30.06
	BUN (mg/dL)	20.1 ± 3.43	16.9 ± 2.02	17.7 ± 1.54	18.6 ± 3.32
	CREA (mg/dL)	0.59 ± 0.049	0.52 ± 0.050 *	0.52 ± 0.037 **	0.55 ± 0.060
	TP (g/dL)	7.38 ± 0.522	7.35 ± 0.386	7.48 ± 0.531	7.38 ± 0.284
	ALB (g/dL)	4.72 ± 0.324	4.78 ± 0.188	4.91 ± 0.368	4.80 ± 0.209
	A/G (ratio)	1.77 ± 0.067	1.86 ± 0.117	1.91 ± 0.101 **	1.87 ± 0.081
	AST (IU/L)	115.2 ± 36.10	122.3 ± 26.10	98.3 ± 12.96	105.5 ± 10.66
	ALT (IU/L)	38.9 ± 29.84	37.8 ± 18.01	29.6 ± 8.36	26.8 ± 4.48
	TBIL (mg/dL)	0.133 ± 0.0215	0.160 ± 0.0204	0.182 ± 0.0213 **	0.194 ± 0.0399 **
	GGT (IU/L)	0.71 ± 0.337	0.93 ± 0.645	0.82 ± 0.364	0.87 ± 0.315
	ALP (IU/L)	170.3 ± 62.04	137.4 ± 45.26	169.1 ± 40.69	174.3 ± 50.54
	TCHO (mg/dL)	66.3 ± 19.06	60.4 ± 15.15	64.8 ± 12.15	63.0 ± 14.01
	TG (mg/dL)	23.5 ± 12.20	18.6 ± 6.68	18.1 ± 4.18	15.1 ± 6.62
	Ca (mg/dL)	11.40 ± 0.444	11.47 ± 0.558	11.53 ± 0.878	11.39 ± 0.306
	IP (mg/dL)	7.85 ± 0.903	8.10 ± 1.212	8.42 ± 1.040	7.93 ± 0.993
	K (mmol/L)	6.90 ± 0.611	7.25 ± 0.799	7.47 ± 0.913	7.17 ± 0.691
	CK (IU/L)	411.6 ± 79.44	527.4 ± 195.99	403.7 ± 102.16	526.1 ± 159.18
	PL (mg/dL)	134.9 ± 30.32	120.3 ± 20.72	132.5 ± 16.77	126.5 ± 15.52
	Na (mmol/L)	143.4 ± 1.35	144.1 ± 1.66	144.9 ± 2.02	145.1 ± 2.18
	Cl (mmol/L)	101.4 ± 2.07	102.2 ± 1.32	101.8 ± 2.04	102.5 ± 1.65

Data are expressed as the mean ± SD, n = 10 animals per group. * p < 0.05, ** p < 0.01 according to Dunnett’s LSD test.

).

3.2.6. Gross Autopsy and Histopathological Examinations

No abnormalities associated with the administration of Yeosinsan were observed by gross autopsy. Regarding visual observation and ophthalmology, no changes associated with the administration of the test substance were observed in any dose group (Table S5).

Under microscopic observations, changes associated with the test substance were observed in the stomach and spleen. In the stomach observation, in the 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), squamous cell hyperplasia of the forestomach was observed to be very weak (minimal) to weak (slight). These changes were observed with vesiculation or neutrophil infiltration at the limiting ridge of the forestomach and the glandular ventriculus. In the spleen observation, in the female 500 mg∙kg⁻¹∙d⁻¹ group and all dose groups at 1000 and 2000 mg∙kg⁻¹∙d⁻¹, extramedullary hematopoiesis was observed to be very weak (minimal) to weak (slight). In the dose groups at or over 500 mg∙kg⁻¹∙d⁻¹, increased pigmentation was observed to be very weak (minimal) to weak (slight). In addition, in the male control group and the male 500 mg∙kg⁻¹∙d⁻¹ dose group, extramedullary hematopoiesis was observed to be very weak (minimal) in 1 and 10 cases, respectively. This was judged to be a change within the normal range. In the observation of the female genitalia (ovary, uterus, and vagina), changes associated with the test substance were not observed. Other observed findings were judged to be spontaneous or accidental changes observed in animals of similar age, given the incidence (

Table 7. Summary of microscopic findings of chronic oral toxicity.

Dosage Group (mg∙kg−1∙d−1)			0	500	1000	2000
Male	Spleen	Number examined	10	10	10	10
		Number unremarkable	9	9	5	0
	Extramedullary hematopoiesis	1>	1	1 a	3 a	3 a
		2>	0	0	0	1 a
		Total finding incidence	1	1 a	3 a	4 a
	Increased pigmentation	1>	0	1 a	3 a	7 a
		2>	0	0	1	3 a
		Total finding incidence	0	1 a	4 a	10 a
	Sternum/Marrow	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Stomach	Number examined	10	10	10	10
		Number unremarkable	10	10	10	9
	Squamous cell hyperplasia, forestomach	1>	0	0	0	1
		Total finding incidence	0	0	0	1
	Testes	Number examined	10	0	0	10
		Number unremarkable	10	0	0	9
	Atrophy, tubules	2>	0	0	0	1
		Total finding incidence	0	0	0	1
Female	Skin, inguinal	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Spinal cord, cervical	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Spinal cord, lumbar	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Spinal cord, thoracic	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Spleen	Number examined	10	10	10	10
		Number unremarkable	10	4	1	0
	Extramedullary hematopoiesis	1>	0	2 a	4 a	4 a
		Total finding incidence	0	2 a	4 a	4 a
	Increased pigmentation	1>	0	5 a	8 a	5 a
		2>	0	0	0	5 a
		Total finding incidence	0	5 a	8 a	10 a
	Sternum/marrow	Number examined	10	0	0	10
		Number unremarkable	10	0	0	10
	Stomach	Number examined	10	10	10	10
		Number unremarkable	10	10	10	7
	Squamous cell hyperplasia, forestomach	1>	0	0	0	2
		2>	0	0	0	1
		Total finding incidence	0	0	0	3
	Thymus	Number examined	10	0	0	10
		Number unremarkable	9	0	0	8
	Epithelial tubules	1>	1	0	0	2
		Total finding incidence	1	0	0	2
	Thyroid and parathyroid glands	Number examined	10	0	0	10
		Number unremarkable	9	0	0	10
	Ectopic thymus	Present	1	0	0	0
		Total finding incidence	1	0	0	0

^a includes the case with multiple symptoms.

). Regarding the photomicrographs shown in Figure 4, the chronic high-dose group showed extramedullary hematopoiesis and increased pigmentation in the spleen. The chronic high-dose group showed squamous cell hyperplasia in the forestomach (Figure 4L,R).

3.2.7. Urine Analysis

In the urinalysis, in male mice the BILu was found to be 1+ to 2+ in 1, 5, and 8 cases of 10 in groups of dose 500, 1000, and 2000 mg∙kg⁻¹∙d⁻¹, respectively. In female mice, the BILu was found to be 1+ to 2+ in 2, 4, and 5 cases of 10, at the same dose as the male groups. Abnormal amounts of BILu in the urine are associated with liver disease. In the 2000 mg∙kg⁻¹∙d⁻¹ dose group (G4), UBG was observed at about 1+ in 2 cases of 10 in both males and females. Other observed changes were judged to be unrelated to the test substance because of a lack of correlation with the dose (Table S6).

4. Discussion

In this study, Yeosinsan, a traditional herbal formula composed of P. lactiflora and C. rotundus, was evaluated for acute and chronic oral toxicity using female and male SD rats. In the acute toxicity experiment, the main findings (single administration of 0, 500, 1000, or 2000 mg/kg of Yeosinsan) indicated no significant alteration in mortality, body weight, general clinical symptoms, or gross pathological signs in either male or female rats. Thus, these results suggest that an approximate acute lethal dose of Yeosinsan is over 2000 mg/kg in rats.

In the chronic toxicity experiment, the main findings indicated no significant alteration in mortality, body weight, general clinical symptoms, food uptake, ophthalmological condition, organ weight, or gross pathological signs following daily treatment with Yeosinsan (0, 500, 1000, or 2000 mg∙kg⁻¹∙d⁻¹ for 13 weeks). However, the hematological, clinical, pathological, and histopathological observations demonstrated several significant changes in these groups. In the histopathological experiments, a minimal to slight squamous hyperplasia of the forestomach was found in the 2000 mg∙kg⁻¹∙d⁻¹ groups. This observation was accompanied by vesiculation or neutrophil infiltration in the limiting ridge of the forestomach. Thus, the change was considered an adverse effect of inflammatory irritation stimulated by the experimental material, according to guidelines and a previous study [23,24].

Previous studies on the toxicity and safety of P. lactiflora and C. rotundus, the component herbs of Yeosinsan, did not report any severe toxicity [14,22]. A network pharmacology study revealed that P. lactiflora has a protective effect against ulcerative colitis [25]. In addition, the combination of P. lactiflora and Inula britannica L. has a protective effect against gastric ulcers induced via the administration of HCl/EtOH solution [26]. An herbal formula composed of C. rotundus, Holarrhena antidysenterica L., and Zingiber officinale Rosc. has been used for abdominal pain [14]. However, no previous study reported the protective or deteriorating effect of C. rotundus on the stomach. The concentration of 2000 mg∙kg⁻¹∙d⁻¹ of Yeosinsan is far from the clinical dose of the ingredient herbs, P. lactiflora and C. rodundus [14,22,27]. Thus, in general clinical use, Yeosinsan could be regarded as a safe herbal formula up to its usual dose.

In the histopathological observation of the spleen, mild extramedullary hematopoiesis was found in the female 500 mg∙kg⁻¹∙d⁻¹ group and all groups at or over 1000 mg∙kg⁻¹∙d⁻¹. The change was characterized as the increase in erythroid lineage cells in the red pulp. These findings were considered to be a regenerative reaction to the decrease in the RBC and increases in RETA, RET%, MCV, and MCH. In addition, very weak increases in pigmentation were observed in the groups at or over 500 mg∙kg⁻¹∙d⁻¹. This appears to be related to the clinicopathological findings such as an increase in TBIL in the serum, increases in BILu and UBG in the urine, and an increase in the relative weight of the spleen. These results appear to be related to hemolytic anemia because damaged RBCs are generally removed by macrophages in the spleen [28]. The effects of P. lactiflora or C. rotundus on hemolytic anemia and histopathological changes in the spleen were not previously reported. P. lactiflora has been regarded as a remedy for anemia caused by iron deficiency and hemolysis [29,30]. Paeoniflorin and albiflorin, the major compounds of P. lactiflora, exhibited a hematopoietic effect on a chemotherapy- or radiotherapy-induced murine myelosuppression model [31,32]. The pathological changes in the spleen induced by chemical hemolysis were also reduced by treatment with P. lactiflora or its component glucosides [30,33]. C. rotundus also showed anti-hemolytic and hemagglutination-inhibitory effects in a carbapenem-resistant bacteria model [34]. In addition, different extracts of C. rotundus did not show any acute toxicity in mice up to a dose of 1 g/kg [35].

However, paeoniflorin, a major component of P. lactiflora, has been reported as an anti-thrombotic agent that acts by upregulating urokinase-type plasminogen activator (uPA) [36]. In the theory of traditional Korean and Chinese herbal medicine, the roots of P. lactiflora and C. rotundus belong to a group of herbs for removing blood stasis [37,38]. These herbal medicines have been generally used for coagulopathy, and they act by activating anti-coagulating factors including uPA and thereby have side effects such as unexpected bleeding [37,39]. Thus, it is possible that a high dose of paeoniflorin, which is contained in Yeosinsan, might be a cause of hemolysis and spleen damage. However, in this study, the RBC counts were slightly decreased and not accompanied by spleen tissue damage. In addition, the findings in the spleen were evaluated as reversible changes owing to adaptive or secondary reactions to hemolysis. Thus, it is believed that the results were not related to the adverse effects of the test material. However, in this study, there are two major limitations. First, the mechanisms underlying the side effects of Yeosinsan were not clearly examined. The issue should be examined by extensive study. Second, Yeosinsan is likely to be used during the initial pregnancy period in clinical practice. Thus, to avoid another toxic side effect on the embryo, additional safety examinations on reproductive toxicity and genotoxicity might be needed for conducting further clinical experiments.

5. Conclusions

Based on these data from acute and chronic toxicology studies, the no observed adverse effect level (NOAEL) of the test material, Yeosinsan, was estimated to be 1000 mg∙kg⁻¹∙d⁻¹ in both male and female rats. In the previous in vivo efficacy study, 15.96 and 31.92 mg∙kg⁻¹∙d⁻¹ of Yeosinsan showed maximal effects on endometrial receptivity and ovarian function, respectively [21]. Because the doses for in vivo efficacy are within the NOAEL in this study, we estimate that Yeosinsan might be safe to use for treating female infertility.